Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005 ; 5 : 230-42.
Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 2003 ; 19 : 607-20.
Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004 ; 21 : 81-93.
Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992 ; 80 : 2326-35.
Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI. The growth fraction of human myeloma cells. Blood 1981 ; 57 : 333-8.
Bakkus MH, Van Riet I, Van Camp B, Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994 ; 87 : 68-74.
Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004 ; 103 : 2332-6.
Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, Angitapalli R, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006 ; 203 : 1859-65.
Wicha MS, Liu S, Dontu G. Cancer stem cells : an old idea - a paradigm shift. Cancer Res 2006 ; 66 : 1883-90 ; (discussion 1895-86).
Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007 ; 104 : 4048-53.
Zweidler-McKay PA, He Y, Xu L, Rodriguez CG, Karnell FG, Carpenter AC, et al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 2005 ; 106 : 3898-906.
Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 2004 ; 101 : 6122-7.
Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007 ; 104 : 7516-21.
Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, et al. Wnts induce migration and invasion of myeloma plasma cells. Blood 2005 ; 106 : 1786-93.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100 : 57-70.
Minvielle S. [Gene expression profiling of multiple myeloma]. Bull Cancer 2003 ; 90 : 127-30.
Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988 ; 332 : 83-5.
Trikha M, Corringham R, Klein B, Rossi JF. Targered anti-interleukin-6 monoclonal antibody therapy for cancer : a review of the rationale and clinical evidence. Clin Cancer Res 2003 ; 9 : 4653-65.
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells : therapeutic implications. Oncogene 2002 ; 21 : 5673-83.
Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B, et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells : study in the 5T33MM model. Br J Cancer 2004 ; 90 : 1076-83.
Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, et al. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma : Beneficial effects on tumor growth, angiogenesis, bone disease and survival, Int J Cancer 2001 ; 121 : 1857-61.
Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004 ; 103 : 3148-57.
Moreaux J, Hose D, Jourdan M, Reme T, Hundemer M, Moos M, et al. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica 2007 ; 92 : 803-11.
Caers J, Gunthert U, De Raeve H, Van Valckenborgh E, Menu E, Van Riet I, et al. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol 2006 ; 132 : 469-77.
Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S, et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 2005 ; 19 : 2166-76.
Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005 ; 23 : 6333-8.
Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 2005 ; 65 : 11345-53.
Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, et al. Tumor suppressor p16 methylation in multiple myeloma : biological and clinical implications. Blood 2001 ; 109 : 1228-32.
Oancea M, Mani A, Hussein MA, Almasan A. Apoptosis of multiple myeloma. Int J Hematol 2004 ; 80 : 224-31.
Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD, et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 2004 ; 113 : 1763-73.
Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002 ; 100 : 194-9.
Schultheis B, Kramer A, Willer A, Hegenbart U, Goldschmidt H, Hehlmann R. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia 1999 ; 13 : 2099-103.
Wu KD, Orme LM, Shaughnessy J, Jacobson J, Barlogie B, Moore MA. Telomerase and telomere length in multiple myeloma : correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 2003 ; 101 : 4982-9.
Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H, et al. Clinical significance of telomerase activity in multiple myeloma. Cancer 2002 ; 94 : 2232-8.
Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Gryaznov S, et al. Telomerase inhibition with an oligonucleotide telomerase template antagonist : in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004 ; 103 : 258-66.
Shammas MA, Shmookler Reis RJ, Li C, Koley H, Hurley LH, Anderson KC, et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res 2004 ; 10 : 770-6.
Esteller M. Cancer epigenomics : DNA methylomes and histone-modification maps. Nat Rev Genet 2007 ; 8 : 286-98.
Dib A, Barlogie B, Shaughnessy JD, Kuehl WM. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 2007 ; 109 : 1337-8.
Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006 ; 66 : 5781-9.
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma : biological and clinical implications. Proc Natl Acad Sci USA 2004 ; 101 : 540-5.
Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K. Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol Dis 2004 ; 33 : 111-9.
Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci 2005 ; 96 : 317-22.
Vande Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B, Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemoractic proteins MCP-1, -2 and -3. Br J Cancer 2003 ; 88 : 855-62.
Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashica K, et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions : a study in the 5TMM model. Clin Exp Metastasis 2006 ; 23 : 291-300.
Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, et al. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 2006 ; 91 : 605-12.
Van Valckenborgh E, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K. Matrix metalloproteinases in multiple myeloma. Cancer Therapy 2004 ; 2A.
Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, et al. Metalloproteinases in multiple myeloma : production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997 ; 90 : 1649-55.
Van Valckenborgh E, Bakkus M, Munaut C, Noel A, St Pierre Y, Asosingh K, et al. Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer 2002 ; 101 : 512-8.
Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, et al. Multifunctional role of matrix metalloproteinases in multiple myeloma : a study in the 5T2MM mouse model. Am J Pathol 2004 ; 165 : 869-78.
Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, et al. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma. Clin Exp Metastasis 2002 ; 19 : 583-91.
Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007 ; 6 : 60-4.
Kirschke H, Eerola R, Hopsu-Havu VK, Bromme D, Vuorio E. Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur J Cancer 2000 ; 36 : 787-95.
Van Riet I, Van Camp B. The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma 1993 ; 9 : 441-52.
Lauta VM. A review of the cytokine network in multiple myeloma : diagnostic, prognostic, and therapeutic implications. Cancer 2003 ; 97 : 2440-52.
Vincent T, Mechti N. IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia 2004 ; 18 : 967-75.
Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance : role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999 ; 93 : 1658-67.
Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 2003 ; 63 : 7900-6.
Dalton WS. Drug resistance in myeloma. Haematologica 2007 ; 92(suppl 2) : 42-3.
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000 ; 407 : 249-57.
Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, et al. Angiogenesis in multiple myeloma. Eur J Cancer 2006 ; 42 : 1581-90.
Zini JM, Tobelem G. [Angiogenesis and hematologic malignancy]. Bull Cancer 2007 ; 94 : S241-S246.
Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994 ; 87 : 503-8.
Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002 ; 8 : 2210-6.
Van Valckenborgh E, De Raeve H, Devy L, Blacher S, Munaut C, Noel A, et al. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 2002 ; 86 : 796-802.
Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B, et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis : role of CD45 heterogeneity. Blood 2004 ; 103 : 3131-7.
Van Riet I, Asosingh K, Vande Broek I, Van Valckenborgh E, De Raeve H, Leleu X, et al. Targeting of vascular endothelial and platelet derived growth factor signaling by receptor tyrosine kinase inhibitors impairs myeloma cell-induced neovascularization in the 5TMM mouse model. Haematologica 2005 ; 90(S1) : 29.
Epstein J, Walker R. Myeloma and bone disease : "the dangerous tango". Clin Adv Hematol Oncol 2006 ; 4 : 300-6.
Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004 ; 350 : 1655-64.
Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma : focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004 ; 32 : 685-91.
Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002 ; 100 : 3002-7.
Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease : Pathophysiology of osteoblast inhibition. Blood 2006 ; 108 : 3992-6.
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002 ; 420 : 860-7.
Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates : friends or foes? Clin Exp Metastasis 2002 ; 19 : 247-58.
De Bruyne E, Bos T, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, et al. Epigenetic silencing of CD9 during MM progression. Haematologica 2007 ; 92(S2) : 114.
Rozman C, Feliu E, Berga L, Reverter JC, Climent C, Ferran MJ. Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes : a stereological study. Exp Hematol 1989 ; 17 : 34-7.
Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia 2007 ; 21 : 1580-4.
Kumar S, Greipp PR, Haug J, Kline M, Chng WJ, Blood E, et al. Gene expression profiling of myeloma cells at diagnosis can predict response to therapy with thalidomide and dexamethasone combination. ASH Annual Meeting Abstracts, 106 : 508, 2005.
Alexandrakis MG, Passam FH, Sfiridaki A, Pappa CA, Moschandrea JA, Kandidakis E, et al. Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers 2004 ; 19 : 52-7.
